Group Sales Growth: 7% overall; 9% excluding COVID-19 impact.<\/p>\n
Core Operating Profit Growth: 14% increase.<\/p>\n
Core Operating Margin: Up 2.1 percentage points.<\/p>\n
Core EPS Growth: 12% excluding tax effects; 7% including tax effects.<\/p>\n
Operating Free Cash Flow: Up 34% to CHF21.2 billion.<\/p>\n
Pharma Sales Growth: 8% at constant exchange rates; 9% excluding Ronapreve.<\/p>\n
Diagnostics Base Business Growth: 8% increase.<\/p>\n
Net Debt: Improved by CHF1.4 billion to CHF17.3 billion.<\/p>\n
Dividend Increase: Increased for the 38th consecutive year.<\/p>\n
IFRS Net Income: Down 19% in constant rates.<\/p>\n
Cash Flow from Operations: CHF20.1 billion reported; CHF21.2 billion in constant rates.<\/p>\n
Pharma Core Operating Profit Margin: 47.7%.<\/p>\n
Diagnostics Core Operating Profit Margin: 16.8% at reported currency.<\/p>\n
Currency Impact on Sales: Minus 4 percentage points.<\/p>\n
Currency Impact on Core EPS: Minus 6 percentage points.<\/p>\n
Release Date: January 30, 2025<\/p>\n
For the complete transcript of the earnings call, please refer to the full earnings call transcript<\/a>.<\/p>\n Roche Holding AG (RHHBF<\/a>) reported a strong overall group sales growth of 7% for 2024, with the base business excluding COVID-19 growing impressively at 9%.<\/p>\n Core operating profit increased by 14%, and the group core operating margin improved by 2.1 percentage points.<\/p>\n The company achieved significant milestones, including EU approval for a prefilled syringe and positive readouts in key trials.<\/p>\n Roche Holding AG (RHHBF<\/a>) increased its dividend for the 38th consecutive year, demonstrating strong shareholder returns.<\/p>\n The company has a robust pipeline with 17 blockbuster medicines and plans for multiple Phase III readouts in 2025, indicating strong future growth potential.<\/p>\n The final impact of COVID-19 sales reduction was CHF1.1 billion, aligning with previous guidance but still a notable decrease.<\/p>\n The loss of exclusivity (LOE) impact was CHF1 billion, slightly better than guidance but still a significant headwind.<\/p>\n IFRS net income decreased by 19% in constant rates, impacted by major impairments and higher interest charges.<\/p>\n Currency fluctuations negatively impacted sales, core operating profit, and core EPS, with a 4% to 6% reduction in each.<\/p>\n The diagnostics division faced challenges with a decline in near patient care sales by 17%, primarily due to lower COVID-19 rapid antigen testing.<\/p>\n Q: How do you see the launch of a prefilled syringe for high-dose EYLEA affecting Everbismo in 2025? A: We are not seeing any impact from high-dose EYLEA. Our prefilled syringe is materially different, offering one-hand administration, which is crucial for ease of use. Everbismo continues to distinguish itself with efficacy and safety, and we expect it to grow and establish itself further. – Teresa Graham, CEO of Roche Pharmaceuticals<\/p>\n Q: Can you provide insights on the commercial potential for high-dose OCREVUS and its impact on IP? A: We haven’t shared commercial expectations yet, but high-dose OCREVUS could offer expanded IP opportunities, especially if combined with new devices. We will provide more details once we have the data. – Teresa Graham, CEO of Roche Pharmaceuticals<\/p>\n Q: What are the expectations for the TL1A program, especially in MASH? A: TL1A is a validated target with anti-fibrotic components, making it suitable for diseases like MASH. We are excited about its potential across various indications and are leveraging our experience in biomarker development. – Teresa Graham, CEO of Roche Pharmaceuticals<\/p>\n Q: Can you elaborate on the potential of the gerodestrant trials and their commercial opportunities? A: We believe gerodestrant has the potential to be a multibillion-dollar franchise, covering the full spectrum of first-line endocrine-sensitive and resistant patients. The trials are designed to cover all patient populations, and we are optimistic about their outcomes. – Teresa Graham, CEO of Roche Pharmaceuticals<\/p>\n Q: What are the strategic focuses for Roche’s pipeline and potential areas for future acquisitions? A: Our focus areas include cardiovascular metabolism, oncology, neurology, immunology, and ophthalmology. We prioritize science-driven acquisitions that fit our strategic agenda, as seen with the Poseida acquisition for CAR-T technology in autoimmune diseases. – Thomas Schinecker, CEO of Roche Group<\/p>\n Q: How does Roche plan to manage margins given the shift towards primary care areas? A: Our goal is to maintain stable margins as a percentage of sales, with potential for expansion. We will continue to focus on cost discipline and strategic investments to support this ambition. – Thomas Schinecker, CEO of Roche Group<\/p>\n Q: What are the next steps for the PASI program in Parkinson’s, and what are the potential outcomes? A: We are evaluating data from the open-label extension and will discuss next steps with regulators. It’s unlikely we would move straight to registration; further trials may be needed. This remains a high-risk, high-reward program. – Teresa Graham, CEO of Roche Pharmaceuticals<\/p>\n Q: Can you provide an update on the development of biomarkers for TL1A and how Roche is positioned in this area? A: We are developing biomarkers as part of our TL1A program, leveraging our expertise in IBD and biomarker development. This positions us well to maximize the potential of TL1A across various indications. – Teresa Graham, CEO of Roche Pharmaceuticals<\/p>\n For the complete transcript of the earnings call, please refer to the full earnings call transcript<\/a>.<\/p>\n